New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
08:58 EDTIPXL, ACTImpax appoints G. Frederick Wilkinson as CEOActavis
Impax Laboratories (IPXL) has appointed G. Frederick Wilkinson as Impax's president and CEO effective April 29. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis (ACT), succeeds Larry Hsu, Ph.D. who is retiring.
News For IPXL;ACT From The Last 14 Days
Check below for free stories on IPXL;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
11:18 EDTACTDepomed announces favorable ruling in Gralise case
Subscribe for More Information
10:32 EDTACTDepomed higher after favorable ruling in Gralise case
Subscribe for More Information
07:26 EDTACTActavis confirms positive results from RECLAIM pivotal Phase III studies
Subscribe for More Information
August 18, 2014
10:06 EDTACTLannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
August 14, 2014
17:31 EDTACTZogenix says Actavis files ANDA for generic version of Zohydro ER
Subscribe for More Information
14:13 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
12:58 EDTACTJANA Partners gives quarterly update on stakes
NEW STAKES: Apache (APA), FMC Corp (FMC), Civeo (CVEO), PetSmart (PETM), and Charter Communications (CHTR). INCREASED STAKES: Actavis (ACT), AIG (AIG), Mallinckrodt (MNK), HD Supply (HDS), and American Capital (ACAS). DECREASED STAKES: Liberty (LVNTA), Oil States International (OIS), eBay (EBAY), Liberty Media (LMCA), and Liberty Interactive (LINTA). LIQUIDATED STAKES: Sirius XM (SIRI), Juniper (JNPR), Golar LNG (GLNG), Outerwall (OUTR), and Teva (TEVA).
12:46 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
August 12, 2014
07:55 EDTACTActavis recent weakness a buying opportunity, says Argus
Subscribe for More Information
August 7, 2014
09:28 EDTACTDepomed may add another pain product to portfolio, says Janney Capital
Subscribe for More Information
August 6, 2014
14:52 EDTACTActavis weakness on tax related concerns overdone, says Sterne Agee
Subscribe for More Information
07:41 EDTIPXLImpax sees FY14 adjusted gross margin as percent of revenue to be upper 50%
Sees FY14 R&d expenses $82M-$88M; Sees FY14 generic R&D expenses $46M-$49M; Sees FY14 brand R&D expenses $36M-$39M; Sees FY14 patent litigation expenses $11M-$13M; Sees FY14 SG&A expenses $115M-$120M; Sees FY14 CapEx $40M-$45M; Sees FY14 Hayward facility remediation costs of $25M-$30M; Sees FY14 effective tax rate of 32%-34%.
07:39 EDTIPXLImpax 'remains excited about business development and M&A landscape'
07:39 EDTIPXLImpax reports Q2 adjusted EPS 60c, consensus 36c
Subscribe for More Information
07:31 EDTACTActavis price target raised to $254 from $237 at UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use